Vaccitech plc (VACC): Price and Financial Metrics

Vaccitech plc (VACC): $2.95

-0.10 (-3.28%)

POWR Rating

Component Grades













Add VACC to Watchlist
Sign Up

Industry: Biotech



in industry

VACC Stock Summary

  • VACC's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than just 4.24% of US-listed equities with positive expected earnings growth.
  • Of note is the ratio of VACCITECH PLC's sales and general administrative expense to its total operating expenses; merely 0.42% of US stocks have a lower such ratio.
  • As for revenue growth, note that VACC's revenue has grown 14,170.52% over the past 12 months; that beats the revenue growth of 99.82% of US companies in our set.
  • Stocks that are quantitatively similar to VACC, based on their financial statements, market capitalization, and price volatility, are BEAM, RPTX, KROS, LYRA, and INMB.
  • VACC's SEC filings can be seen here. And to visit VACCITECH PLC's official web site, go to

VACC Valuation Summary

  • In comparison to the median Healthcare stock, VACC's price/earnings ratio is 60.79% lower, now standing at 8.9.
  • Over the past 21 months, VACC's price/sales ratio has gone down 97.

Below are key valuation metrics over time for VACC.

Stock Date P/S P/B P/E EV/EBIT
VACC 2023-01-20 2.6 0.4 8.9 -10.1
VACC 2023-01-19 2.6 0.4 8.9 -10.1
VACC 2023-01-18 2.7 0.4 8.9 -10.0
VACC 2023-01-17 2.7 0.4 9.0 -9.9
VACC 2023-01-13 2.7 0.4 8.9 -10.0
VACC 2023-01-12 2.7 0.4 8.9 -10.0

VACC Stock Price Chart Interactive Chart >

Price chart for VACC

VACC Price/Volume Stats

Current price $2.95 52-week high $10.45
Prev. close $3.05 52-week low $2.02
Day low $2.89 Volume 39,100
Day high $3.28 Avg. volume 42,228
50-day MA $2.45 Dividend yield N/A
200-day MA $3.73 Market Cap 110.03M

Vaccitech plc (VACC) Company Bio

Vaccitech plc is a clinical-stage biopharmaceutical company that engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing AZD1222, a COVID-19 vaccine. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.

VACC Latest News Stream

Event/Time News Detail
Loading, please wait...

VACC Latest Social Stream

Loading social stream, please wait...

View Full VACC Social Stream

Latest VACC News From Around the Web

Below are the latest news stories about VACCITECH PLC that investors may wish to consider to help them evaluate VACC as an investment opportunity.

Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

OXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and application in tolerogenic immunotherapies for celiac disease and other autoimmune diseases on Monday, November 28, 2022 at 4:30 pm ET. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infec

Yahoo | November 21, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're beginning the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday morning!

William White on InvestorPlace | November 17, 2022

Analysts Are Bullish on These Healthcare Stocks: RAPT Therapeutics (RAPT), Vaccitech Plc (VACC)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on RAPT Therapeutics (RAPT – Research Report), Vaccitech Plc (VACC – Research Report) and LAVA Therapeutics (LVTX – Research Report) with bullish sentiments. RAPT Therapeutics (RAPT) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on RAPT Therapeutics today and set a price target of $50.00. The company's shares closed last Friday at $24.17. According to TipRanks.

Catie Powers on TipRanks | November 14, 2022

Vaccitech Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

Vaccitech ( NASDAQ:VACC ) Third Quarter 2022 Results Key Financial Results Revenue: US$6.17m (up by US$6.15m from 3Q...

Yahoo | November 13, 2022

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer. “This has been a very exciting qua

Yahoo | November 10, 2022

Read More 'VACC' Stories Here

VACC Price Returns

1-mo 39.80%
3-mo 7.27%
6-mo -39.18%
1-year N/A
3-year N/A
5-year N/A
YTD 25.53%
2022 -78.85%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6435 seconds.